双重靶向Akt/mTOR信号通路治疗致命性前列腺癌的前景。 - Suppr

Suppr

超能文献

The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer.

作者信息

Floc'h Nicolas, Abate-Shen Cory

出版信息

Oncotarget. 2012 Dec;3(12):1483-4. doi: 10.18632/oncotarget.771.

DOI:10.18632/oncotarget.771

PMID:23242005

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3681479/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c9a/3681479/e286b3888dba/oncotarget-03-1483-g001.jpg

相似文献

The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer.双重靶向Akt/mTOR信号通路治疗致命性前列腺癌的前景。

Oncotarget. 2012 Dec;3(12):1483-4. doi: 10.18632/oncotarget.771.

Targeting PI3 kinase/AKT/mTOR signaling in cancer.靶向癌症中的PI3激酶/AKT/mTOR信号通路。

Crit Rev Oncog. 2012;17(1):69-95. doi: 10.1615/critrevoncog.v17.i1.60.

Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.横纹肌肉瘤中 PI3K/Akt/mTOR 和 Ras/MEK/ERK 通路抑制的合成致死相互作用。

Cancer Lett. 2013 Sep 1;337(2):200-9. doi: 10.1016/j.canlet.2013.05.010. Epub 2013 May 16.

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.针对非小细胞肺癌中的 PI3K/AKT/mTOR 通路。

Biochem Pharmacol. 2014 Aug 1;90(3):197-207. doi: 10.1016/j.bcp.2014.05.011. Epub 2014 May 24.

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.PI3K/Akt/mTOR 抑制剂在癌症中的应用：从实验室到临床。

Semin Cancer Biol. 2019 Dec;59:125-132. doi: 10.1016/j.semcancer.2019.07.009. Epub 2019 Jul 16.

PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.PI3K/Akt/mTOR 通路抑制剂在胰腺神经内分泌肿瘤治疗中的应用。

Cancer Lett. 2013 Jul 10;335(1):1-8. doi: 10.1016/j.canlet.2013.02.016. Epub 2013 Feb 16.

Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.利用辐射诱导的信号来增加耐药癌细胞对靶向药物的敏感性：以 AKT 和 mTOR 抑制剂为例。

Mol Cancer Ther. 2018 Feb;17(2):355-367. doi: 10.1158/1535-7163.MCT-17-0262. Epub 2017 Aug 11.

Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.靶向PI3K/Akt/mTOR信号通路治疗前列腺癌放射抗性

Crit Rev Oncol Hematol. 2015 Dec;96(3):507-17. doi: 10.1016/j.critrevonc.2015.07.005. Epub 2015 Jul 18.

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.PI3K/AKT/mTOR 通路中癌症治疗的分子靶点。

Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9.

Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.靶向淋巴瘤中的PI3激酶（PI3K）、AKT和mTOR轴

Br J Haematol. 2014 Oct;167(1):19-32. doi: 10.1111/bjh.13065. Epub 2014 Aug 6.

引用本文的文献

Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats.自噬在去势大鼠雄激素诱导的良性前列腺增生中的作用。

Exp Ther Med. 2018 Mar;15(3):2703-2710. doi: 10.3892/etm.2018.5772. Epub 2018 Jan 19.

Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.印度北部前列腺癌患者中ETS和非ETS畸变的分子特征分析。

Prostate. 2015 Jul 1;75(10):1051-62. doi: 10.1002/pros.22989. Epub 2015 Mar 23.

Molecular pathways and targets in prostate cancer.前列腺癌中的分子途径与靶点

Oncotarget. 2014 Sep 15;5(17):7217-59. doi: 10.18632/oncotarget.2406.

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.利用靶向二代测序技术鉴定肝细胞癌中PI3K/AKT/mTOR信号通路的新型治疗靶点

Oncotarget. 2014 May 30;5(10):3012-22. doi: 10.18632/oncotarget.1687.

Immunosuppressants in cancer prevention and therapy.癌症预防与治疗中的免疫抑制剂

Oncoimmunology. 2013 Dec 1;2(12):e26961. doi: 10.4161/onci.26961. Epub 2013 Nov 6.

TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.从 TOR 角度探讨胰岛素抵抗与糖尿病并发症：内分泌学家和老年病学家的观点。

Cell Death Dis. 2013 Dec 12;4(12):e964. doi: 10.1038/cddis.2013.506.

Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.癌症患者使用 mTOR 抑制剂依维莫司和替西罗莫司治疗相关死亡率的发生率和风险：一项荟萃分析。

PLoS One. 2013 Jun 13;8(6):e65166. doi: 10.1371/journal.pone.0065166. Print 2013.

本文引用的文献

Increased survival with enzalutamide in prostate cancer after chemotherapy.恩杂鲁胺可提高化疗后前列腺癌患者的生存率。

N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15.

Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.双重靶向 Akt/mTOR 信号通路抑制遗传工程小鼠模型中的去势抵抗性前列腺癌。

Cancer Res. 2012 Sep 1;72(17):4483-93. doi: 10.1158/0008-5472.CAN-12-0283. Epub 2012 Jul 19.

Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益

N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.PTEN 缺陷型前列腺癌中 PI3K 和雄激素受体信号的相互反馈调节。

Cancer Cell. 2011 May 17;19(5):575-86. doi: 10.1016/j.ccr.2011.04.008.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.

Integrative genomic profiling of human prostate cancer.人类前列腺癌的综合基因组分析。

Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24.

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.去势抵抗性前列腺癌的生物学特性：针对雄激素受体信号轴的靶向治疗

J Clin Oncol. 2005 Nov 10;23(32):8253-61. doi: 10.1200/JCO.2005.03.4777.

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.多西他赛与雌莫司汀对比米托蒽醌和泼尼松治疗晚期难治性前列腺癌的疗效

N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.多西他赛联合泼尼松或米托蒽醌联合泼尼松用于晚期前列腺癌治疗

N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720.

Will mTOR inhibitors make it as cancer drugs?mTOR抑制剂能成为抗癌药物吗？

Cancer Cell. 2003 Nov;4(5):343-8. doi: 10.1016/s1535-6108(03)00275-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验